UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 177

Sortiert nach

It's moving day: factors affecting peripheral blood stem mobilization and strategies for improvement

British journal of haematology, 2003-08, Vol.122 (3), p.360-375

2003

Link zum Volltext

Verfügbarkeit prüfen

A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

Cytotherapy (Oxford, England), 2009, Vol.11 (8), p.992-1001

2009

Link zum Volltext

Verfügbarkeit prüfen

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib

Leukemia & lymphoma, 2009-01, Vol.50 (10), p.1676-1686

2009

Link zum Volltext

Verfügbarkeit prüfen

Current Clinical Indications for Plerixafor

Transfusion medicine and hemotherapy, 2013-08, Vol.40 (4), p.246-250

Fruehauf, Stefan

2013

Link zum Volltext

Verfügbarkeit prüfen

Insertion of Retroviral Vectors in NOD/SCID Repopulating Human Peripheral Blood Progenitor Cells Occurs Preferentially in the Vicinity of Transcription Start Regions and in Introns

Molecular therapy, 2004-11, Vol.10 (5), p.874-881

2004

Link zum Volltext

Verfügbarkeit prüfen

Generation of efficient human blood progenitor–targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells

Experimental hematology, 2008-08, Vol.36 (8), p.957-964

2008

Link zum Volltext

Verfügbarkeit prüfen

Combination Treatment of Imatinib-sensitive and -resistant BCR-ABL-positive CML Cells with Imatinib and Farnesyltransferase Inhibitors

Anticancer research, 2006-05, Vol.26 (3A), p.2169-2177

2006

Link zum Volltext

Verfügbarkeit prüfen

Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)

Clinical cancer research, 2024-04, Vol.30 (7), p.1256

2024

Link zum Volltext

Verfügbarkeit prüfen

Impact of number and size of colorectal metastases (CRM) on survival in patients with RAS wild-type metastatic colorectal cancer treated within the PanaMa trial (AIO KRK 0212)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3551-3551

2023

Link zum Volltext

Verfügbarkeit prüfen

Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic CRC: Analysis of patients treated within the PanaMa trial (AIO KRK 0212)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.127-127

2023

Link zum Volltext

Verfügbarkeit prüfen

Viral Determinants of Integration Site Preferences of Simian Immunodeficiency Virus-Based Vectors

Journal of Virology, 2006-08, Vol.80 (16), p.8145-8150

2006

Link zum Volltext

Verfügbarkeit prüfen

Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212)

European journal of cancer (1990), 2023-01, Vol.178, p.37-48

2023

Link zum Volltext

Verfügbarkeit prüfen

Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study

Advances in therapy, 2016-11, Vol.33 (11), p.1983-2000

2016

Link zum Volltext

Verfügbarkeit prüfen

Neurobehavioral toxicity of total body irradiation: a follow-up in long-term survivors

International journal of radiation oncology, biology, physics, 2000-01, Vol.46 (2), p.303-311

2000

Link zum Volltext

Verfügbarkeit prüfen

The Disparate Twins: A Comparative Study of CXCR4 and CXCR7 in SDF-1α-Induced Gene Expression, Invasion and Chemosensitivity of Colon Cancer

Clinical cancer research, 2014-02, Vol.20 (3), p.604-616

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 177

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(159)
Mit Volltextzugriff
(161)

Publikationsform

Sprache

Englisch
(173)
Japanisch
(13)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(92)
Life Sciences & Biomedicine
(87)
Humans
(83)
Oncology
(46)
Hematology
(43)
Female
(32)
Male
(26)
Middle Aged
(26)
Adult
(24)
Biological And Medical Sciences
(23)
Biotechnology & Applied Microbiology
(21)
Medical Sciences
(21)
Animals
(18)
Medicine, Research & Experimental
(17)
Research & Experimental Medicine
(17)
Cell Biology
(16)
Mice
(16)
Aged
(15)
Hematopoietic Stem Cell Transplantation
(14)
Cell & Tissue Engineering
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

It's moving day: factors affecting peripheral blood stem mobilization and strategies for improvement

A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib

Current Clinical Indications for Plerixafor

Insertion of Retroviral Vectors in NOD/SCID Repopulating Human Peripheral Blood Progenitor Cells Occurs Preferentially in the Vicinity of Transcription Start Regions and in Introns

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)

Generation of efficient human blood progenitor–targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells

Combination Treatment of Imatinib-sensitive and -resistant BCR-ABL-positive CML Cells with Imatinib and Farnesyltransferase Inhibitors

Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)

Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial

Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)

Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212)

Impact of number and size of colorectal metastases (CRM) on survival in patients with RAS wild-type metastatic colorectal cancer treated within the PanaMa trial (AIO KRK 0212)

Size-related heterogeneity of colorectal liver metastases (CRLM) in patients with advanced RAS wild-type metastatic colorectal cancer (mCRC) treated in the PanaMa trial: Implication for treatment decisions

Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: An analysis of the Panama trial (AIO KRK0212)

Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic CRC: Analysis of patients treated within the PanaMa trial (AIO KRK 0212)

Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab-FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212)

Predictive and prognostic value of carcinoembryonic antigen (CEA) on maintenance therapy with 5-fluoruracil/leucovorin plus panitumumab or 5-fluoruracil/leucovorin alone in RAS wildtype metastatic colorectal cancer: Evaluation of the phase II PanaMa trial (AIO KRK 0212)

Negative hyperselection for mutations associated with anti-EGFR antibody resistance in RAS wildtype metastatic colorectal cancer (mCRC): Evaluation of the PANAMA trial (AIO-KRK-0212, maintenance therapy with 5-FU, folinic acid (FU/FA) with or without panitumumab)

Viral Determinants of Integration Site Preferences of Simian Immunodeficiency Virus-Based Vectors

Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212)

Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study

Impact of age and gender on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC): Subgroup analysis of the PANAMA-study (AIO-KRK-0212)

Neurobehavioral toxicity of total body irradiation: a follow-up in long-term survivors

The Disparate Twins: A Comparative Study of CXCR4 and CXCR7 in SDF-1α-Induced Gene Expression, Invasion and Chemosensitivity of Colon Cancer

Suchergebnisse filtern